Switch to:
More From Other Websites
AstraZeneca results to get lift from bid foe Pfizer Jul 25 2014
Zacks Industry Outlook Highlights: Pfizer, AstraZeneca, AbbVie, Shire and Mylan Jul 25 2014
The Zacks Analyst Blog Highlights: Starbucks, Dunkin' Brands, Bristol-Myers Squibb, AstraZeneca and... Jul 25 2014
Obama Goes On The Attack Against Companies Doing Inversions To Move To Countries Where They Pay Less... Jul 25 2014
Premier Biomedical Gears Up for Two Important Clinical Trials Jul 25 2014
Pfizer Ltd’s Profit from operations before other income, finance cost and tax for the Quarter... Jul 25 2014
Bristol-Myers profit tops forecasts, helped by newer drugs Jul 24 2014
Botox Maker’s Bosses Put Money Where Their Mouths Are Jul 24 2014
Pfizer Needs to Do a Deal, Analyst Says Jul 24 2014
Michigan governor's campaign met with ambivalence Jul 24 2014
Did Pfizer Make A Horrible Business Deal? Jul 24 2014
[video] Caterpillar CEO sees mining 'green shoots' Jul 24 2014
[video] Eli Lilly looking for smaller acquisitions: CEO Jul 24 2014
[video] Results hurt by patent expirations: Eli Lilly CEO Jul 24 2014
More Questions Raised About Boehringer Ingelheim's Pradaxa Jul 23 2014
[video] Faber Report: Puma Biotech surges Jul 23 2014
Puma Biotech up more than 270% in one day Jul 23 2014
Prempro Plaintiffs’ Lawyers Settle $62 Million Fee Fight Jul 23 2014
[video] Don't Expect Tax Inversion Fever to Break Anytime Soon Jul 22 2014
Top U.S. lawmaker wants corporate tax loophole 'plugged now' Jul 22 2014

Add Notes, Comments or Ask Questions

User Comments

ReplySEENSCO - 1 month ago
PFE is trading at the low end of our short-term valuation range ($29-$36) and significantly below our Fair Value estimate of $42.41.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
Email Hide